Results from the POSEIDON Trial were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2012. Data showed a ...
The PC Trial data presented at TCT 2012 looked at transcather PFO closure vs. medical therapy in preventing cryptogenic ...
More than 350,000 deaths occur each year as a result of sudden cardiac arrest (SCA), which occurs when the heart abruptly and unexpectedly stops beating. A survey issued by the Heart Rhythm Society (HRS) shows a lack of awareness of SCA and the treatment options. In fact, 75 percent of Americans are unaware that an implantable cardioverter defibrillator (ICD) is an effective treatment option to protect those at risk of SCA. In October, HRS highlights SCA Awareness Month with its annual "Apples and Oranges" campaign to raise awareness for SCA and help educate the general public about risk factors and life-saving therapies.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
November 9, 2012 — Boston Scientific Corp. has received approval to update the directions for use (DFU) labeling for Promus Element and Promus Element Plus coronary drug eluting stent (DES) systems to include three-month dual antiplatelet therapy (DAPT).
November 9, 2012 — Svelte Medical Systems announced it received conditional approval from the U.S. Food and Drug Administration (FDA) to begin a pivotal study for the Svelte coronary stent integrated delivery system (IDS).
November 9, 2012 — The U.S. Food and Drug Administration (FDA) recently cleared Bolton Medical’s Relay Thoracic Stent Graft with Plus Delivery System.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
November 9, 2012 — A study found that the use of rosuvastatin prior to angioplasty did not influence the levels of troponin I, a sensitive indicator of muscle damage. Results were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
November 9, 2012 — Bristol-Myers Squibb Co. and Pfizer Inc. announced that the reductions in stroke or systemic embolism, major bleeding, and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation. These results of a subanalysis from the ARISTOTLE clinical trial were published in The Lancet.
Toshiba’s advanced radiation dose reduction technology, Adaptive Iterative Dose Reduction 3D (AIDR 3D), is now available ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Toshiba will showcase Spot Fluoro, a dose management tool for Infinix-i vascular X-ray systems. Spot Fluoro allows clinicians to view a region of anatomy using live fluoroscopy while viewing the Last Image Hold surrounding area, resulting in lower dose and a larger image display area than offered by previous technology.
November 8, 2012 — Results of the RESPECT clinical trial, presented at TCT 2012, indicates that using an investigational medical device to close a PFO, or “hole in the heart,” may be superior to medical management alone in the prevention of a repeated stroke.
November 8, 2012 — A hydration regimen tailored to the patient’s fluid status was effective in reducing damage to kidneys in patients undergoing cardiac catheterization, according to a study presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 8, 2012 — A U.S. Food and Drug Administration (FDA) advisory committee is meeting Dec. 5 to discuss how to classify and regulate intra-aortic balloon pumps (IABPs), which have been grandfathered without clear policy since the FDA tightened regulations on medical devices in the late 1970s. The panel will also discuss classifications for two other grandfathered technologies, including external counter-pulsating (ECP) devices and cardiopulmonary bypass blood pumps.
November 8, 2012 — Boston Scientific Corp. is extending its reach into the renal denervation market by signing a definitive agreement to acquire Vessix Vascular Inc. Vessix Vascular has developed a catheter-based renal denervation system for the treatment of uncontrolled hypertension. The acquisition is expected to close by the end of November 2012.
The results of the FAME II Trial were presented at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting. The ...